Nephrocare Health Services has released the audio recording of its investors' conference call regarding the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The conference call was held on May 20, 2026, and the recording is now available on the company's official website. This disclosure follows the company's announcement of its financial performance for the period, which highlighted significant growth in revenue and profitability.

Financial Performance Overview

The company reported a consolidated net profit of ₹30.4 crore for Q4 FY26, marking a year-on-year increase of 22.1%. For the full fiscal year, revenue grew significantly to ₹998.8 crore, an increase of 32.2% compared to ₹755.8 crore in FY25. The Adjusted PAT for the full year stood at ₹128.3 crore, reflecting a 74.6% increase from the previous year.

Key Financial Metrics

The following table summarises the key financial metrics for Q4 and FY26 on a year-on-year basis:

Operational and Strategic Highlights

Nephrocare Health Services recorded a notable rise in both revenue and net profit during Q4 FY26. Revenue growth was driven by a 15.2% increase in treatment volumes and a favorable mix shift towards international markets. The company noted that international revenue contribution rose from 31.8% in FY25 to 41.8% in FY26. The Return on Capital Employed (RoCE) for FY26 was reported at 22.8%, a growth of 290 basis points. The firm continues to leverage its asset-light model, with approximately 52% of clinics operating under a revenue-sharing arrangement.

Nephrocare Health Services Limited has reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board, in its meeting held on May 19, 2026, approved the results along with several strategic decisions regarding its overseas subsidiaries.

For the financial year ended March 31, 2026, the company reported a net loss of ₹80.60 million, a significant shift from the net profit of ₹342.36 million recorded in the previous year. Revenue from operations for the year increased to ₹6,297.43 million from ₹5,435.97 million in the prior year. In the quarter ended March 31, 2026, the company returned to profitability with a net profit of ₹108.88 million, compared to a net profit of ₹56.72 million in the corresponding quarter of the previous year.

The board approved a further investment of up to ₹10 crore in Nephrocare Health Services Nepal Private Limited, its wholly owned subsidiary. This investment will be made in one or more tranches towards meeting business operations, working capital requirements, and general corporate purposes. Additionally, the board granted in-principal approval for providing collateral or security support aggregating up to ₹70 crore each to two overseas subsidiaries: Nephrocare Health Services International Pte. Ltd. in Singapore and Nephrocare Health Services Saudi Arabia Company. These guarantees are intended to enable the subsidiaries to avail credit facilities from overseas banks.

The company also re-appointed M/s. BDO India LLP as the Internal Auditor for the financial year 2026-27 based on the recommendations of the Audit Committee. The statutory auditors, M/s. B S R and Co, issued an audit report with an unmodified opinion on the standalone and consolidated financial results.

Standalone Financial Results

The standalone financial performance for the year reflects the impact of non-cash and non-recurring items. The company incurred an interest expense of ₹371.89 million on financial liabilities measured at fair value through profit or loss during the year. Total expenses for the year rose to ₹6,489.46 million from ₹5,138.68 million in the previous year.

Consolidated Financial Results

On a consolidated basis, the group reported a net profit of ₹768.40 million for the year ended March 31, 2026, up from ₹670.96 million in the previous year. Revenue from operations for the group stood at ₹9,988.45 million for the year. The profit for the quarter ended March 31, 2026, was ₹303.70 million.